

Raymond C W Hutubessy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6838976/publications.pdf>

Version: 2024-02-01

65
papers

3,447
citations

218677

26
h-index

144013

57
g-index

69
all docs

69
docs citations

69
times ranked

4488
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimating the cost of COVID-19 vaccine deployment and introduction in Ghana using the CVIC tool. <i>Vaccine</i> , 2022, 40, 1879-1887.	3.8	5
2	Costs of seasonal influenza vaccination in South Africa. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 873-880.	3.4	5
3	WHO-led consensus statement on vaccine delivery costing: process, methods, and findings. <i>BMC Medicine</i> , 2022, 20, 88.	5.5	12
4	Economic evaluation of seasonal influenza vaccination in elderly and health workers: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2022, 47, 101410.	7.1	12
5	A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme. <i>Vaccine</i> , 2021, 39, 412-422.	3.8	17
6	Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1598-1610.	9.1	34
7	The CAPACITI Decision-Support Tool for National Immunization Programs. <i>Value in Health</i> , 2021, 24, 1150-1157.	0.3	9
8	Programme costs for introducing age/gestation-based universal influenza vaccine schedules for young children and pregnant women in Hong Kong. <i>Vaccine</i> , 2021, 39, 6762-6780.	3.8	3
9	Systematic Review on the Acute Cost-of-illness of Sepsis and Meningitis in Neonates and Infants. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 35-40.	2.0	14
10	Parent, provider and vaccinee preferences for HPV vaccination: A systematic review of discrete choice experiments. <i>Vaccine</i> , 2020, 38, 7226-7238.	3.8	12
11	A review of the costs of delivering maternal immunisation during pregnancy. <i>Vaccine</i> , 2020, 38, 6199-6204.	3.8	9
12	How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-making. <i>Vaccine: X</i> , 2020, 6, 100078.	2.1	8
13	Costing oral cholera vaccine delivery using a generic oral cholera vaccine delivery planning and costing tool (CholTool). <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 3111-3118.	3.3	2
14	â€˜It takes two to tangoâ€™: Bridging the gap between country need and vaccine product innovation. <i>PLoS ONE</i> , 2020, 15, e0233950.	2.5	7
15	The case for assessing the full value of new tuberculosis vaccines. <i>European Respiratory Journal</i> , 2020, 55, 1902414.	6.7	8
16	Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. <i>Lancet</i> , The, 2020, 395, 575-590.	13.7	421
17	Comparing 3 Approaches for Making Vaccine Adoption Decisions in Thailand. <i>International Journal of Health Policy and Management</i> , 2020, 9, 439-447.	0.9	4
18	Guidelines for multi-model comparisons of the impact of infectious disease interventions. <i>BMC Medicine</i> , 2019, 17, 163.	5.5	39

#	ARTICLE	IF	CITATIONS
19	A Scoping Review of Investment Cases for Vaccines and Immunization Programs. <i>Value in Health</i> , 2019, 22, 942-952.	0.3	11
20	Rationale and opportunities in estimating the economic burden of seasonal influenza across countries using a standardized WHO tool and manual. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 13-21.	3.4	15
21	Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia. <i>Health Policy and Planning</i> , 2018, 33, 204-214.	2.7	14
22	Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination. <i>Vaccine</i> , 2018, 36, 2529-2544.	3.8	49
23	WHO guide on the economic evaluation of influenza vaccination. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 211-219.	3.4	25
24	Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework. <i>Pharmacoeconomics</i> , 2018, 36, 79-90.	3.3	13
25	Global economic evaluation of oral cholera vaccine: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 420-429.	3.3	13
26	Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report. <i>Value in Health</i> , 2018, 21, 1133-1149.	0.3	94
27	Model Comparisons of the Effectiveness and Cost-Effectiveness of Vaccination: A Systematic Review of the Literature. <i>Value in Health</i> , 2018, 21, 1250-1258.	0.3	21
28	Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability. <i>Vaccine</i> , 2018, 36, 3993-3997.	3.8	15
29	Global economic evaluations of rotavirus vaccines: A systematic review. <i>Vaccine</i> , 2017, 35, 3364-3386.	3.8	25
30	Economic evaluations of <i>Haemophilus influenzae</i> type b (Hib) vaccine: a systematic review. <i>Journal of Medical Economics</i> , 2017, 20, 1094-1106.	2.1	6
31	Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects. <i>PLoS ONE</i> , 2017, 12, e0182663.	2.5	43
32	Maternal influenza immunization in Malawi: Piloting a maternal influenza immunization program costing tool by examining a prospective program. <i>PLoS ONE</i> , 2017, 12, e0190006.	2.5	16
33	Identification and Prioritization of the Economic Impacts of Vaccines. <i>BioMed Research International</i> , 2016, 2016, 1-8.	1.9	2
34	Cost-effectiveness thresholds: pros and cons. <i>Bulletin of the World Health Organization</i> , 2016, 94, 925-930.	3.3	518
35	Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 245-252.	2.1	32
36	Rotavirus vaccines contribute towards universal health coverage in a mixed public-private healthcare system. <i>Tropical Medicine and International Health</i> , 2016, 21, 1458-1467.	2.3	4

#	ARTICLE	IF	CITATIONS
37	Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich Countries. <i>Health Affairs</i> , 2016, 35, 227-234.	5.2	15
38	Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. <i>Pharmacoeconomics</i> , 2016, 34, 227-244.	3.3	97
39	A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda. <i>Vaccine</i> , 2015, 33, 7357-7363.	3.8	33
40	The broader economic impact of vaccination: reviewing and appraising the strength of evidence. <i>BMC Medicine</i> , 2015, 13, 209.	5.5	106
41	Estimating costs of care for meningitis infections in low- and middle-income countries. <i>Vaccine</i> , 2015, 33, A240-A247.	3.8	27
42	Stakeholders' perception on including broader economic impact of vaccines in economic evaluations in low and middle income countries: a mixed methods study. <i>BMC Public Health</i> , 2015, 15, 356.	2.9	19
43	A systematic review of the social and economic burden of influenza in low- and middle-income countries. <i>Vaccine</i> , 2015, 33, 6537-6544.	3.8	91
44	Costs of Introducing and Delivering HPV Vaccines in Low and Lower Middle Income Countries: Inputs for GAVI Policy on Introduction Grant Support to Countries. <i>PLoS ONE</i> , 2014, 9, e101114.	2.5	70
45	Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. <i>The Lancet Global Health</i> , 2014, 2, e406-e414.	6.3	194
46	Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts. <i>BMC Medicine</i> , 2013, 11, 23.	5.5	24
47	Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. <i>Vaccine</i> , 2013, 31, 5430-5434.	3.8	15
48	Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review. <i>Vaccine</i> , 2013, 31, 3786-3804.	3.8	91
49	Influenza vaccines in low and middle income countries. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1500-1511.	3.3	50
50	Costs of Illness Due to Cholera, Costs of Immunization and Cost-Effectiveness of an Oral Cholera Mass Vaccination Campaign in Zanzibar. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1844.	3.0	46
51	Decision-making on malaria vaccine introduction: the role of cost-effectiveness analysis. <i>Bulletin of the World Health Organization</i> , 2012, 90, 864-866.	3.3	18
52	Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. <i>BMC Public Health</i> , 2012, 12, 878.	2.9	96
53	A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool. <i>BMC Medicine</i> , 2012, 10, 136.	5.5	45
54	Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. <i>BMC Medicine</i> , 2012, 10, 137.	5.5	46

#	ARTICLE	IF	CITATIONS
55	Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world. BMC Medicine, 2011, 9, 84.	5.5	34
56	Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Medicine, 2011, 9, 54.	5.5	37
57	Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools. BMC Medicine, 2011, 9, 53.	5.5	18
58	Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal. BMC Medicine, 2011, 9, 55.	5.5	26
59	WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine, 2010, 28, 2356-2359.	3.8	145
60	Cost effectiveness analysis of strategies for child health in developing countries. BMJ: British Medical Journal, 2005, 331, 1177.	2.3	126
61	Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Effectiveness and Resource Allocation, 2003, 1, 8.	1.5	390
62	Critical issues in the economic evaluation of interventions against communicable diseases. Acta Tropica, 2001, 78, 191-206.	2.0	22
63	The Full Value of Vaccine Assessments (FVVA): A Framework to Assess and Communicate the Value of Vaccines for Investment and Introduction Decision Making. SSRN Electronic Journal, 0, , .	0.4	21
64	Assessing fitness-for-purpose and comparing the suitability of COVID-19 multi-country models for local contexts and users. Gates Open Research, 0, 5, 79.	1.1	1
65	Modeling anticipated changes in numbers of SARS-CoV-2 infections within communities due to immunization campaigns. Gates Open Research, 0, 6, 7.	1.1	1